Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice

Stem Cells

Volumn 26, Issue 8, 2008, Pages 2075-2082

  Morigi, Marina ^a   Introna, Martino ^b   Imberti, Barbara ^a   Corna, Daniela ^a   Abbate, Mauro ^a   Rota, Cinzia ^a   Rottoli, Daniela ^a   Benigni, Ariela ^a   Perico, Norberto ^a   Zoja, Carla ^a   Rambaldi, Alessandro ^b   Remuzzi, Andrea ^a   Remuzzia, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Acute renal failure; Human mesenchymal stem cells; Kidney repair; Tubular cells

Indexed keywords

CISPLATIN;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CONVALESCENCE; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LEUKOCYTE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; MOUSE; NONHUMAN; RENAL PROTECTION;

ANIMALS; APOPTOSIS; BODY WEIGHT; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CISPLATIN; FEMALE; HUMANS; KIDNEY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; PHENOTYPE;

MUS; RODENTIA;

EID: 55049087497     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0795     Document Type: Article

References (57)

1. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
2. Schrier RW, Wang W, Poole B et al. Acute renal failure: Definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114:5-14.
3. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
4. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: Time to consider combination therapy. Semin Nephrol 2000;20:4-19.
5. Grino JM. BN 52021: A platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation. Ann Intern Med 1994;121:345-347.
6. Haug CE, Colvin RB, Delmonico FL et al. A phase I trial of immuno-suppression with antiICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993;55:766-772.
7. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005;23:845-856.
8. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006;441:1094-1096.
9. Aejaz HM, Aleem AK, Parveen N et al. Stem cell therapy - Present status. Transplant Proc 2007;39:694-699.
10. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
11. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001.
12. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004;117:5655-5664.
13. Hung SC, Pochampally RR, Chen SC et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. STEM CELLS 2007;25:2363-2370.
14. Tögel F, Hu Z, Weiss K et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-F42.
15. Majumdar MK, Thiede MA, Haynesworth SE et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000;9:841-848.
16. Al-Khaldi A, Al-Sabti H, Galipeau J et al. Therapeutic angiogenesis using autologous bone marrow stromal cells: Improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003;75:204-209.
17. Tang J, Xie Q, Pan G et al. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006;30:353-361.
18. Nagaya N, Fujii T, Iwase T et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004;287:H2670-H2676.
19. Kinnaird T, Stabile E, Burnett MS et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109:1543-1549.
20. Morigi M, Imberti B, Zoja C et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004;15:1794-1804.
21. Herrera MB, Bussolati B, Bruno S et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004;14:1035-1041.
22. Kunter U, Rong S, Djuric Z et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:2202-2212.
23. Bi B, Schmitt R, Israilova M et al. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007;18:2486-2496.
24. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301-308.
25. Imberti B, Morigi M, Tomasoni S et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007;18:2921-2928.
26. Tögel F, Weiss K, Yang Y et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007;292:F1626-F1635.
27. Basile DP. The endothelial cell in ischemic acute kidney injury: Implications for acute and chronic function. Kidney Int 2007;72:151-156.
28. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003;14(suppl 1):S55-S61.
29. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211:27-35.
30. Capelli C, Domenghini M, Borleri G et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007;40:785-791.
31. Witzgall R, Brown D, Schwarz C et al. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994;93:2175-2188.
32. Kawada H, Fujita J, Kinjo K et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104:3581-3587.
33. Wang XJ, Li QP. The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases. Biochem Biophys Res Commun 2007;359:189-193.
34. Jin HK, Carter JE, Huntley GW et al. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002;109:1183-1191.
35. Bae JS, Han HS, Youn DH et al. Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. STEM CELLS 2007;25:1307-1316.
36. Onda T, Honmou O, Harada K et al. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 2008;28:329-340.
37. Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy 2005;7:36-45.
38. Bianco P, Riminucci M, Gronthos S et al. Bone marrow stromal stem cells: Nature, biology, and potential applications. STEM CELLS 2001;19:180-192.
39. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996;166:585-592.
40. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
41. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
42. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
43. Koç ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
44. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95.
45. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
46. Humphreys BD, Valerius MT, Kobayashi A et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008;2:284-291.
47. Herrera MB, Bussolati B, Bruno S et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007;72:430-441.
48. François S, Bensidhoum M, Mouiseddine M et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: A study of their quantitative distribution after irradiation damage. STEM CELLS 2006;24:1020-1029.
49. Ludwig T, Riethmuller C, Gekle M et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004;66:196-202.
50. Zwelling LA, Kohn KW. Mechanism of action of cis- dichlorodiammineplatinum(II). Cancer Treat Rep 1979;63:1439-1444.
51. Huang Q, Dunn RT 2nd, Jayadev S et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001;63:196-207.
52. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
53. Zhang B, Ramesh G, Norbury CC et al. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007;72:37-44.
54. Kelly KJ, Meehan SM, Colvin RB et al. Protection from toxicant-mediated renal injury in the rat with antiCD54 antibody. Kidney Int 1999;56:922-931.
55. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985;249:F490-F496.
56. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002;62:1539-1549.
57. Deen WM, Bridges CR, Brenner BM et al. Heteroporous model of glomerular size selectivity: Application to normal and nephrotic humans. Am J Physiol 1985;249:F374-F389.